Market research
ITH.F Nektar Therapeutics
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 29.08
- Dividend yield
- Not available
- Beta
- 0.56
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6402681083
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 29.08
- Dividend yield
- Not available
- Beta
- 0.56
About
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ITH.F discussion.
5 years, 5 months ago
Nektar Therapeutics is currently in a long term downtrend where the price is trading 10.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.8.
Nektar Therapeutics's total revenue sank by 30.7% to $23M since the same quarter in the previous year.
Its net income has dropped by 3.3% to $-117M since the same quarter in the previous year.
Finally, its free cash flow grew by 22.1% to $-100M since the same quarter in the previous year.
Based on the above factors, Nektar Therapeutics gets an overall score of 2/5.